Featured Blog Posts – October 2015 Archive (4)
Staff PPMD Submits Results of Patient-Centered Benefit-Risk Assessment Study in Duchenne & Becker to FDA
PPMD is pleased to announce that late yesterday we submitted the results of our most recent patient-centered benefit-risk assessment (PCBR) study to the FDA. The assessment was done with research partners at the Johns Hopkins Bloomberg School…
ContinueAdded by PPMD on October 22, 2015 at 7:48am — No Comments
Staff Ad Comms Update: Group Letter Submitted to FDA
PPMD is proud to help author and share the attached letter to Dr. Janet Woodcock, Director of the…
ContinueAdded by PPMD on October 19, 2015 at 11:00am — No Comments
Staff Ad Comms Update: An Overwhelming Day
Today we learned that the FDA will host an Advisory Committee (Ad Comm) meeting on November 24 to discuss the…
ContinueAdded by Pat Furlong on October 14, 2015 at 4:30pm — No Comments
Staff PPMD Urges Senate to Move Forward on #Cures2015 Innovation for Healthier Americans Bill
Yesterday, I had the distinct privilege of representing PPMD and our Duchenne community as I sat before a full room of Senate staffers and congressional aides in the Dirksen Senate office building. Our goal was to urge them to press forward on the Innovation for Healthier Americans bill (also referred to as the ‘Innovation…
ContinueAdded by Annie Kennedy on October 9, 2015 at 12:00pm — 1 Comment
Latest Featured Blog Posts
- PPMD Designates UC Davis a Certified Duchenne Care Center
- PPMD Working with FDA to Plan Landmark Pediatric Advisory Committee Meeting to Improve Clinical Trial Experience
- PPMD's Duchenne Drug Development Roundtable Meeting Series, Part 3: Clinical Trial Readiness from the Viewpoint of Clinicians and Infrastructure
- ACTION ALERT: Make Your Voice Heard on New Healthcare Proposal
- PPMD's Duchenne Drug Development Roundtable Meeting Series, Part 2: Optimizing Clinical Trials
- PPMD Designates Ann & Robert H. Lurie Children's Hospital of Chicago a Certified Duchenne Care Center
- Marathon Pharmaceuticals Pauses Commercialization of EMFLAZA™ (deflazacort)
Most Popular Featured Blog Posts
- FDA Grants Accelerated Approval to First Drug for Duchenne Muscular Dystrophy
- Deflazacort Approved in the U.S. for Duchenne
- A Historic Day for Duchenne
- Early morning calls
- Action ALERT: Urge Congress to Vote YES on 21st Century Cures Act
- PPMD Announces Gene Therapy Forum
- What You Need to Know about Duchenne & Viral Gastroenteritis (That Horrible Stomach Bug!)
Featured Monthly Archives
2017
2016
- December (1)
- November (1)
- October (3)
- September (2)
- August (2)
- July (2)
- June (1)
- May (2)
- April (2)
- March (6)
- February (4)
- January (3)
2015
- December (3)
- November (3)
- October (4)
- September (5)
- August (5)
- July (6)
- June (3)
- May (2)
- April (4)
- March (3)
- February (5)
- January (7)
2014
- December (2)
- November (3)
- October (5)
- September (3)
- August (1)
- July (2)
- June (1)
- May (3)
- April (3)
- March (1)
- February (1)
- January (1)
2013
- December (5)
- November (4)
- October (6)
- September (5)
- August (3)
- July (5)
- June (3)
- May (6)
- April (3)
- March (6)
- February (7)
- January (2)
2012
- December (3)
- November (5)
- October (12)
- September (11)
- August (8)
- July (4)
- June (5)
- May (5)
- April (5)
- March (8)
- February (6)
- January (5)
2011
- December (5)
- November (11)
- October (9)
- September (6)
- August (3)
- July (1)
- June (3)
- May (2)
- April (6)
- March (3)
- February (4)
- January (4)
2010
- December (4)
- November (2)
- October (2)
- September (4)
- August (3)
- July (3)
- June (3)
- May (3)
- April (4)
- February (1)
- January (6)
2009
- December (5)
- November (7)
- October (1)
- September (3)
- August (5)
- July (2)
- May (2)
- April (2)
- March (4)
- February (3)
- January (1)
2008
© 2018 Created by PPMD.
Powered by
Badges | Report an Issue | Privacy Policy | Terms of Service
